RU2006127475A - Композиции и способы лечения рецидивирующих медицинских состояний - Google Patents

Композиции и способы лечения рецидивирующих медицинских состояний Download PDF

Info

Publication number
RU2006127475A
RU2006127475A RU2006127475/14A RU2006127475A RU2006127475A RU 2006127475 A RU2006127475 A RU 2006127475A RU 2006127475/14 A RU2006127475/14 A RU 2006127475/14A RU 2006127475 A RU2006127475 A RU 2006127475A RU 2006127475 A RU2006127475 A RU 2006127475A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmacological agent
specified
medical condition
Prior art date
Application number
RU2006127475/14A
Other languages
English (en)
Russian (ru)
Inventor
Джейсон МАКДЭВИТТ (US)
Джейсон МАКДЭВИТТ
Майкл ДЭВИС (US)
Майкл ДЭВИС
Original Assignee
Джейсон МАКДЭВИТТ (US)
Джейсон МАКДЭВИТТ
Майкл ДЭВИС (US)
Майкл ДЭВИС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джейсон МАКДЭВИТТ (US), Джейсон МАКДЭВИТТ, Майкл ДЭВИС (US), Майкл ДЭВИС filed Critical Джейсон МАКДЭВИТТ (US)
Publication of RU2006127475A publication Critical patent/RU2006127475A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2006127475/14A 2003-12-29 2004-12-29 Композиции и способы лечения рецидивирующих медицинских состояний RU2006127475A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53300303P 2003-12-29 2003-12-29
US60/533,003 2003-12-29
US62525304P 2004-11-05 2004-11-05
US60/625,253 2004-11-05

Publications (1)

Publication Number Publication Date
RU2006127475A true RU2006127475A (ru) 2008-02-10

Family

ID=34752985

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006127475/14A RU2006127475A (ru) 2003-12-29 2004-12-29 Композиции и способы лечения рецидивирующих медицинских состояний

Country Status (8)

Country Link
US (2) US7846913B2 (cg-RX-API-DMAC7.html)
EP (1) EP1703907A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007517049A (cg-RX-API-DMAC7.html)
KR (1) KR20070007276A (cg-RX-API-DMAC7.html)
AU (1) AU2004311869A1 (cg-RX-API-DMAC7.html)
CA (1) CA2592631A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006127475A (cg-RX-API-DMAC7.html)
WO (1) WO2005065308A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
CA2609972C (en) * 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2007018801A1 (en) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
ATE515259T1 (de) * 2007-05-29 2011-07-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit eszopiclon
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
US20100204291A1 (en) * 2009-02-12 2010-08-12 Mcdevitt Jason P Method for Facilitating Extinction Training Using D-Cycloserine
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX336979B (es) * 2011-12-16 2016-02-09 Senosiain S A De C V Lab Combinacion farmaceutica antineuritica y composiciones.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2025173704A1 (ja) * 2024-02-16 2025-08-21 エフバイタル株式会社 薬剤のスクリーニング方法、および剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CA2372073A1 (en) * 1999-04-29 2000-11-09 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycine cleavage system inhibitors as potential antipsychotics
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations

Also Published As

Publication number Publication date
US20050143314A1 (en) 2005-06-30
JP2007517049A (ja) 2007-06-28
US8309535B2 (en) 2012-11-13
KR20070007276A (ko) 2007-01-15
AU2004311869A1 (en) 2005-07-21
US20110071102A1 (en) 2011-03-24
CA2592631A1 (en) 2005-07-21
EP1703907A2 (en) 2006-09-27
US7846913B2 (en) 2010-12-07
WO2005065308A2 (en) 2005-07-21
EP1703907A4 (en) 2009-03-25
WO2005065308A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
EP0839040A1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
JP2005516913A5 (cg-RX-API-DMAC7.html)
JP2007517049A5 (cg-RX-API-DMAC7.html)
CN101244244A (zh) 一种治疗抑郁症的药物组合物及其制备方法
ES2212549T3 (es) Combinaciones farmaceuticas que contienen tramadol.
CN1652806A (zh) 可用于治疗雄性和雌性性无能的制剂
CN120774998B (zh) 一种治疗男性勃起功能障碍的组合物及其应用
CN101062080A (zh) 一种具有抗疲劳作用的药物组合物及其制备方法
KR20200014289A (ko) 우울증을 치료하기 위한 조성물 및 방법
CN120775005B (zh) 一种多肽组合物及其在用于治疗男性勃起功能障碍中的用途
US5897864A (en) Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
CA2528312A1 (en) Methods of managing the symptoms of premenstrual syndrome
JP2019535758A (ja) リドカイン無効状態および低カリウム血症状態の治療のための療法
CN101073333A (zh) 多味解乏饼干
JP4648193B2 (ja) 医薬組成物
CN1342467A (zh) 一种治疗重症肌无力的药物
RU2358723C1 (ru) Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
JP2021518438A5 (cg-RX-API-DMAC7.html)
RU2010139840A (ru) Комбинация противораковых агентов
CN102755320A (zh) 治疗关节炎之药物组合物及保健食品
US20060269623A1 (en) Herbal composition and method of use for promoting erections and treating erectile dysfunction in men
CN100551410C (zh) 一种抗抑郁药物及制备方法
CN1256976C (zh) 一种抗癌中药组合物及其制备方法
CN101204412A (zh) 治疗骨质疏松症的复方中药
CN103948666B (zh) 一种治疗糖尿病藏药的制备方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090327